Longitudinal stability of cerebrospinal fluid biomarker levels: Fulfilled requirement for pharmacodynamic markers in Alzheimer’s disease

Manuscript Number: 

11-0029R1

Author(s): 
Laetitia Aerts, Peter P. De Deyn, Sebastiaan Engelborghs, Nathalie Le Bastard, Jean-Jacques Martin, Kristel Sleegers, Christine Van Broeckhoven

Disclosures

Laetitia Aerts

  • Nothing to Disclose

Peter P. De Deyn

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Consulting Fees:
    Past consultant for Innogenetics (-2011); past member of the Innogenetics Advisory Board Dementia (-2011); past member of the Janssen-Cilag Advisory Board Dementia (-2011); past member of the UCB Advisory Board on Epilepsy (-2011); member Janssen / Pfizer European Alzheimer̢��‰�s Disease Scientific Advisory Board; member Souvenaid Advisory Board, Nutricia Advanced Medical Nutrition; member of Alzheimer̢��‰�s Disease Assay Expert Group Advisory Board (ADAEG), Roche Diagnostics.
    Grants
    • Agency: 
      Educational grant, Lundbeck Belgium
      Dates: 
      2010
    • Agency: 
      Educational grant, Janssen Belgium
      Dates: 
      2010

Nathalie Le Bastard

  • Nothing to Disclose

Jean-Jacques Martin

  • Nothing to Disclose

Kristel Sleegers

  • Nothing to Disclose

Christine Van Broeckhoven

  • Nothing to Disclose